The cleanest read on the
HRT telehealth market.

Top-scored is Winona (8.4/10), which holds the current set's highest Transparency Grade (B): compounded bioidentical HRT with a true $0-consult model from $54/mo, every product priced before intake, and ~6,000 Trustpilot reviews at ~4.7. For a labs-first workup with the biggest verified review base in hormone telehealth, Hone Health (7.5/10) is the alternative: a $25/mo membership plus medication (real all-in $53-$180+). All five women's-wing platforms we track are cash-pay; none bills insurance directly.

Verified July 2026: the five women's-wing platforms run $25-$149/mo depending on product and provider, all cash-pay. The cheapest all-inclusive route is Winona at $54/mo with nothing else to pay ($0 consult). Hone Health's labs-first model floors around $53/mo all-in. Watch the framing: Hone's advertised $25/mo is a membership, not a treatment price (real all-in $53-$180+), Hers' $79/mo requires a 12-month plan, and Gala's $79/mo is a public starting price with other formats unpriced pre-intake.

Most commercial plans cover FDA-approved HRT medications (generic estradiol, micronized progesterone), often with step-therapy rules; compounded bioidentical HRT is almost never covered. None of the five women's-wing telehealth platforms we currently track bill insurance directly: Winona, Hone Health, Hers, Inner Balance, and Gala Health are all cash-pay (several are HSA/FSA eligible). The way to use insurance is to fill an FDA-approved prescription at your own pharmacy on your plan's formulary.

Our A-F grade for what a provider discloses BEFORE you hand over an email address, separate from the 0-10 quality score. Five criteria: pricing disclosed pre-intake, named clinicians with credentials, published cancellation policy, corporate disclosure, and third-party review accessibility. Current spread across the 7 providers we track: one B (Winona, the ceiling: full pre-intake pricing but thin corporate disclosure), three C (Hone Health, PeterMD, Gala Health), and three D (Hers, Inner Balance, Maximus, which gate pricing or leave clinicians unnamed).

In November 2025 the FDA began removing black-box warnings (for cardiovascular disease, breast cancer, and dementia) from menopausal hormone therapy products, with labeling changes approved in February 2026, and demand surged. Estrogen-patch prescriptions are up 184% since 2018 (Truveta). Multiple estradiol patch products from Amneal, Zydus, Sandoz, Noven and Viatris are now on the ASHP shortage list (including Amneal's Dotti), though the FDA has not added estradiol patches to its own shortage database. Gel, spray, and pill alternatives are not in shortage; our live tracker shows which providers can switch you.

Yes. A clearly-labeled second wing at /trt covers 3 TRT providers under the same methodology and transparency grading. The short version: real all-in TRT cost is $53-$180+/mo, not the $25 marketing number (that's a membership fee, not a treatment price). Highest-scored is Hone Health (7.5/10, labs-first); the budget pick is PeterMD from $99/mo, with a BBB file worth reading first; Maximus specializes in enclomiphene and oral-TRT protocols (but carries a BBB F, so we cap its score at 7.0).

A 0-10 score on fixed weights (cost 25%, formulary 20%, clinical depth 20%, patient experience 20%, transparency 15%) plus a separate A-F Transparency Grade. Two hard rules: affiliate status is excluded from score computation, and any provider with an unanswered BBB F rating is capped at 7.0 no matter how good the rest looks (currently applied to Maximus). Every price carries a Verified or Reported status label with the verification date.

We earn commissions when readers sign up with some of the platforms listed, disclosed on every page. Our score is methodology-driven, never adjusted for affiliate status: if a higher-scored platform pays less than a lower-scored one, the higher-scored one ranks higher anyway. Where we have no independent review data we say 'Not surfaced' instead of inventing ratings. Full firewall details in our editorial policy.